Actinium Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Actinium Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 94% of Healthcare companies in United States.
- Cash Cushion Ratio: Cash, after subtracting all debt, equals 92% of its market value (net cash). Higher than 87% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-391.7×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 94% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 2/3Sales grew in 1 of the last 3 years; profit grew in 2 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 91%
Sales fell 91% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-91% / -55%In 3 years sales changed by -91% while total assets changed by -55%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-34.0×Operating cash was negative last year, while some debt falls due within a year.
Lower than 65% of Healthcare companies in United States.
Cash Cushion Ratio
+92%Cash, after subtracting all debt, equals 92% of its market value (net cash).
Higher than 87% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Actinium Pharmaceuticals, Inc. owes $0.25 for every $1 it owns. Actinium Pharmaceuticals, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
4.4Investors pay $4.4 for every $1 of Actinium Pharmaceuticals, Inc.'s yearly profit, lower than 87% of Healthcare companies in United States.
P/B ratio
1.66The share price is 1.66 times Actinium Pharmaceuticals, Inc.'s book value per share, lower than 65% of Healthcare companies in United States.
Market cap
$50 MThe total market value of all of Actinium Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), smaller than 74% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$30 MWhat Actinium Pharmaceuticals, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.96Net worth divided by the number of shares. The share price of $1.60 is 1.7 times this, which is the P/B above.
Return on equity (ROE)
45.9%Actinium Pharmaceuticals, Inc. earned 45.9% on its shareholders' money over the last year, higher than 96% of Healthcare companies in United States.
Owes vs Owns
0.25×Actinium Pharmaceuticals, Inc. owes $0.25 for every $1 it owns (low), lower than 67% of Healthcare companies in United States.
Dividend yield
NoneActinium Pharmaceuticals, Inc. does not currently pay a dividend.
Profit growth
LossActinium Pharmaceuticals, Inc. made a loss in each of the last two years.
Profit margin
-37652.2%Actinium Pharmaceuticals, Inc. lost $37652 for every $100 of revenue.
Cash vs debt
Net cashActinium Pharmaceuticals, Inc. held $46 M more cash than debt (net cash) at Dec 2025.
Questions
What is Actinium Pharmaceuticals, Inc.'s P/E ratio?
Investors pay $4.4 for every $1 of Actinium Pharmaceuticals, Inc.'s yearly profit, lower than 87% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Actinium Pharmaceuticals, Inc.: $50 M ÷ $30 M (30 Jun 2026) = 1.7.
What is Actinium Pharmaceuticals, Inc.'s return on equity?
Actinium Pharmaceuticals, Inc. earned 45.9% on its shareholders' money over the last year, higher than 96% of Healthcare companies in United States.
How much does Actinium Pharmaceuticals, Inc. owe compared with what it owns?
Actinium Pharmaceuticals, Inc. owes $0.25 for every $1 it owns (low), lower than 67% of Healthcare companies in United States.
Does Actinium Pharmaceuticals, Inc. pay a dividend?
No. Actinium Pharmaceuticals, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.